This video reviews ongoing trials testing immunotherapy for patients with head and neck cancer.
In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses two ongoing trials testing immunotherapy in different settings for patients with head and neck cancer.
The first, a phase III trial, is testing standard of care vs pembrolizumab or chemotherapy plus pembrolizumab in patients with metastatic head and neck cancer.
The second trial is studying the efficacy of pembrolizumab prior to salvage surgery in patients whose disease has recurred after already having received definitive chemoradiation.
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.